Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of BMS-986218 alone or with nivolumab in advanced solid tumors
MOH_2018-04-24_000838Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BMS-986218, nivolumab and ipilimumab in Nonhematologic neoplasms (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability and Dose selection. Started Feb 2018; status: active, not recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2018-04-24_000838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-24_000838.